Skip to main content

Advertisement

Table 1 Non-compartmental analysis parameter estimates of the exposure of ferroquine and SSR97213

From: A Phase II pilot trial to evaluate safety and efficacy of ferroquine against early Plasmodium falciparum in an induced blood-stage malaria infection study

  Ferroquine SSR97213
Cmax (ng/mL)
 Geometric mean 155 89
 Log-linear CIs (94–257) (49–162)
Tmax (h)
 Median (range) 6 (4–8) 8 (4–12) one subject at 48 h)
C144 h (ng/mL)
 Geometric mean 26 26
 Log-linear CIs (21–32) (19–36)
Half-life (h)
 Geometric mean 262 (10.9 days) 661 (27.5 days)
 Range (204–315) (295–1349)
AUC144 h (ng/mL)
 Geometric mean 6893 5525
 Log-linear CIs (5378–8834) (3883–7861)
AUC0−last (ng/mL)
 Geometric mean 12,406 12,247
 Range (9259–17,826) (6449–19,975)
AUC0−Inf (ng/mL)
 Geometric mean 16,631 31,006
 Range (11,314–25,091) (10,061–55,768)